Farallon Sells ~2.6M Exelixis Shares Into Rally, Drops Below 5% Stake
EXEL sits 81% above its 52-week low of $39.71 on elevated volume (2.0× avg).
Summary
Farallon Capital cut its Exelixis stake to 4.9% from 5.6%, selling about 2.6 million shares in October and early November at $60.96-$72.60 — largely into the stock's run to 52-week highs.
Key Events · Ownership and Investor Activity · EXEL
-
Farallon Drops Below 5% Threshold
Farallon Capital reported 12,017,906 shares, or 4.9% of the 244,010,895 shares outstanding as of October 19, 2026, and ceased to be a beneficial owner of more than 5% on November 6, 2026.
-
~2.6M Shares Sold in 60 Days
Exhibit 1.D shows sales from October 14 to November 6, 2026, including 568,000 shares at $69.84 on October 30 and 255,661 at $72.60 on November 3, versus purchases in September at $57.07-$60.11.
-
Selling Into 52-Week Highs
Sale prices of $60.96-$72.60 compare with a 52-week high of $73.69, indicating profit-taking into strength rather than distress selling.
-
Prior Filing Showed 5.6% and Buying
The August 14, 2026 Schedule 13D/A reported a 5.6% stake with net buying of about 1 million shares; the position has since been reduced.
Analysis · EXEL · Life Sciences
A long-time large holder, Farallon Capital, sold roughly 2.6 million shares between October 14 and November 6 and now holds 12.0 million shares, or 4.9% — below the 5% threshold that requires 13D reporting. The sales came at $60.96 to $72.60, i.e. into a stock trading near its 52-week high of $73.69, and reverse the buying Farallon did in September at $57-$60. This is a financial investor taking profits, not an operational signal, but it removes a large holder's support and puts roughly 12 million shares of remaining overhang in play. Note the August 14 filing showed Farallon at 5.6% and net buying; the direction has now flipped.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EXEL was trading at $71.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.5B. The 52-week trading range was $39.71 to $73.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.